Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Sickle Cell Disease

There's no cure for sickle cell disease, but spotting it early can improve treatment

Most of the global cases of sickle cell disease are diagnosed in African countries. The Economist Intelligence Unit – the research and analysis division of the Economist media group – estimated that in 2020 the total annual cost of treatment and impact on the economy of sickle cell disease across…

The Conversation

Why Precision BioSciences Shares Are Surging Today

Why Precision BioSciences Shares Are Surging Today

Precision BioSciences Inc (NASDAQ:DTIL) has entered into an exclusive worldwide in vivo gene editing research and development collaboration and license agreement with Novartis AG (NYSE:NVS) Precision will develop a custom ARCUS nuclease that will be designed to insert, in vivo, a therapeutic transgene at a "safe harbor" location in the genome as a potential one-time…

Read Why Forma Therapeutics' Current Price Level Is 'Attractive Entry Point'

Read Why Forma Therapeutics' Current Price Level Is 'Attractive Entry Point'

During the European Hematology Association (EHA) conference, Forma Therapeutics Holdings Inc (NASDAQ:FMTX) presented updated results from the 12-week open-label extension (OLE) of etavopivat's Phase 1 trial in sickle cell disease. Treatment with etavopivat 400mg QD elicited a >1g/dL hemoglobin (Hb) increase in 73% of the 15 patients and an average maximal Hb increase of…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

FDA Sounds Positive On Bluebird's One Gene Therapy But Doubts Another

The FDA signaled in briefing documents released that it may approve Bluebird bio Inc's (NASDAQ:BLUE) beti-cel gene therapy to treat β-thalassemia for those who require regular blood transfusions. The Prescription Drug User Fee Act (PDUFA) goal dates for beti-cel and eli-cel are August 19 and September 16. Bluebird bio's blood disorder treatment demonstrates "clinically meaningful"…

Why This Analyst Has 'Little Conviction' On CRISPR's Upcoming Trial Data

RBC Capital Markets says it remains on the sidelines given commercial uptake for CRISPR Therapeutics' (NASDAQ: CRSP) sickle cell disease (SCD)/beta-thalassemia (BT) capped by preconditioning and has little conviction in BCMA/CD70 data within weeks. The analysts lowered its price target to $85 from $95 to reflect higher Opex, with a Sector Perform rating. As recently…

Organisations

RBC Capital Markets

Vertex Pharmaceuticals Incorporated

Precision BioSciences

Economist Intelligence Unit

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

Prescription Drug

Sickle Cell Disease

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

314,276 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play